CN100386070C - 包含褪黑激素的药物制剂 - Google Patents

包含褪黑激素的药物制剂 Download PDF

Info

Publication number
CN100386070C
CN100386070C CNB038075644A CN03807564A CN100386070C CN 100386070 C CN100386070 C CN 100386070C CN B038075644 A CNB038075644 A CN B038075644A CN 03807564 A CN03807564 A CN 03807564A CN 100386070 C CN100386070 C CN 100386070C
Authority
CN
China
Prior art keywords
melatonin
zolpidem
chemical compound
pharmaceutical preparation
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038075644A
Other languages
English (en)
Chinese (zh)
Other versions
CN1646098A (zh
Inventor
N·齐萨佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100386070(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CN1646098A publication Critical patent/CN1646098A/zh
Application granted granted Critical
Publication of CN100386070C publication Critical patent/CN100386070C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038075644A 2002-04-08 2003-03-20 包含褪黑激素的药物制剂 Expired - Lifetime CN100386070C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL149377 2002-04-08
IL149377A IL149377A (en) 2002-04-28 2002-04-28 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds

Publications (2)

Publication Number Publication Date
CN1646098A CN1646098A (zh) 2005-07-27
CN100386070C true CN100386070C (zh) 2008-05-07

Family

ID=29227410

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038075644A Expired - Lifetime CN100386070C (zh) 2002-04-08 2003-03-20 包含褪黑激素的药物制剂

Country Status (29)

Country Link
US (1) US20050175692A1 (enExample)
EP (1) EP1494650B1 (enExample)
JP (1) JP2005527583A (enExample)
KR (1) KR101000624B1 (enExample)
CN (1) CN100386070C (enExample)
AR (1) AR039232A1 (enExample)
AT (1) ATE507831T1 (enExample)
AU (1) AU2003227304B2 (enExample)
BR (1) BR0308762A (enExample)
CA (1) CA2477516C (enExample)
DE (1) DE60336999D1 (enExample)
DK (1) DK1494650T3 (enExample)
EA (1) EA007954B1 (enExample)
ES (1) ES2366116T3 (enExample)
GT (1) GT200300064A (enExample)
HN (1) HN2003000115A (enExample)
IL (1) IL149377A (enExample)
IS (1) IS2858B (enExample)
MX (1) MXPA04009893A (enExample)
NO (1) NO332525B1 (enExample)
NZ (1) NZ536298A (enExample)
PE (1) PE20040161A1 (enExample)
PL (1) PL209922B1 (enExample)
PT (1) PT1494650E (enExample)
TW (1) TW200305404A (enExample)
UA (1) UA86924C2 (enExample)
UY (1) UY27753A1 (enExample)
WO (1) WO2003086352A1 (enExample)
ZA (1) ZA200407563B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
US20060198872A1 (en) * 2005-03-07 2006-09-07 Chioma Ikonte Plant based dietary supplement for improving the duration and quality of sleep
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
CN1299680C (zh) * 2005-08-29 2007-02-14 陈彦方 一种治疗失眠的黑白制剂
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
CN102018681A (zh) * 2010-12-10 2011-04-20 荣港生技医药科技（北京）有限公司 一种美乐托宁缓释剂、其制备方法及其应用
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) * 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP2570126B1 (en) * 2011-09-16 2014-03-26 Darius Rassoulian Use of melatonin for treating acute alcohol intoxication
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
EP3777842B1 (en) * 2016-10-31 2024-12-11 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
CN109364031A (zh) * 2018-10-07 2019-02-22 威海贯标信息科技有限公司 一种盐酸曲唑酮片剂组合物
US11723862B2 (en) * 2020-01-17 2023-08-15 Societe Des Produits Nestle S.A. Dosage form with sustained release melatonin pellets

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172431A (zh) * 1995-02-01 1998-02-04 纽里姆药品(1991)有限公司 褪黑激素在治疗药物成瘾之患者中的应用
US5879710A (en) * 1994-04-01 1999-03-09 Biotec Centre S.A. Heterofunctional mucoadhesive pharmaceutical dosage composition
US6034105A (en) * 1996-07-17 2000-03-07 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
CN1267548A (zh) * 1999-03-18 2000-09-27 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
US6274635B1 (en) * 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
DE69713294T3 (de) * 1996-03-08 2009-01-15 Takeda Pharmaceutical Co. Ltd. Tricyclische Verbindungen mit Bindungsaffinität für Melatoninrezeptoren, deren Herstellung und Verwendung
AU2583397A (en) * 1996-04-10 1997-10-29 Chronorx, Llc Unit dosage forms, containing magnesium, vitamin c, vitamin e, folate and selenium, for treatment of vasoconstriction and related conditions
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879710A (en) * 1994-04-01 1999-03-09 Biotec Centre S.A. Heterofunctional mucoadhesive pharmaceutical dosage composition
CN1172431A (zh) * 1995-02-01 1998-02-04 纽里姆药品(1991)有限公司 褪黑激素在治疗药物成瘾之患者中的应用
US6034105A (en) * 1996-07-17 2000-03-07 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
CN1267548A (zh) * 1999-03-18 2000-09-27 胡秀云 一种由褪黑素和安定制成的调节睡眠的组合物
US6274635B1 (en) * 1999-03-22 2001-08-14 Immugen Pharmaceuticals Inc. Alkylated resorcinol derivatives for the treatment of immune diseases

Also Published As

Publication number Publication date
PT1494650E (pt) 2011-08-18
BR0308762A (pt) 2005-01-11
EA007954B1 (ru) 2007-02-27
IL149377A0 (en) 2009-02-11
KR101000624B1 (ko) 2010-12-10
HN2003000115A (es) 2004-04-20
KR20040101406A (ko) 2004-12-02
MXPA04009893A (es) 2005-06-17
HK1075616A1 (zh) 2005-12-23
PL209922B1 (pl) 2011-11-30
PE20040161A1 (es) 2004-03-22
AU2003227304A2 (en) 2005-04-14
IL149377A (en) 2012-10-31
IS7492A (is) 2004-10-07
ZA200407563B (en) 2005-11-30
NZ536298A (en) 2008-09-26
WO2003086352A1 (en) 2003-10-23
EP1494650B1 (en) 2011-05-04
EA200401331A1 (ru) 2005-04-28
EP1494650A1 (en) 2005-01-12
PL372867A1 (en) 2005-08-08
TW200305404A (en) 2003-11-01
IS2858B (is) 2013-12-15
ATE507831T1 (de) 2011-05-15
DE60336999D1 (de) 2011-06-16
CN1646098A (zh) 2005-07-27
AU2003227304B2 (en) 2007-12-06
CA2477516A1 (en) 2003-10-23
US20050175692A1 (en) 2005-08-11
NO20043576L (no) 2004-12-22
AR039232A1 (es) 2005-02-09
EP1494650A4 (en) 2006-07-12
NO332525B1 (no) 2012-10-08
AU2003227304A1 (en) 2003-10-27
UY27753A1 (es) 2003-05-30
JP2005527583A (ja) 2005-09-15
ES2366116T3 (es) 2011-10-17
GT200300064A (es) 2003-11-26
CA2477516C (en) 2012-12-11
DK1494650T3 (da) 2011-08-08
UA86924C2 (ru) 2009-06-10

Similar Documents

Publication Publication Date Title
Mihic et al. Hypnotics and sedatives
Charney et al. Hypnotics and sedatives
CN100386070C (zh) 包含褪黑激素的药物制剂
US20250302771A1 (en) Treatment of opioid use disorder, opioid withdrawal symptoms and chronic pain
US20080207601A1 (en) Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
JP2007517040A (ja) 睡眠の質を改善するためのメラトニン併用療法
JP2016504405A (ja) ガレヌス製剤の有効成分の投与剤形
US6344487B1 (en) Treatment of insomnia
SI9620022A (sl) Uporaba melatonina za odvajanje od zasvojenosti
KR20190086712A (ko) 리도카인-비유효 병태 및 저칼륨혈성 병태의 치료를 위한 요법
HK1075616B (en) Pharmaceutical formulation comprising melatonin
TW201806599A (zh) 用於快速開始抗抑鬱作用之給藥方案
FUNCTIONING SLEEP MORE!
MX2007008323A (es) Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico.
Singh et al. Pharmacotherapeutic options for treatment of insomnia
Braich et al. Pharmacotherapeutic options for treatment of insomnia.
HK40031715A (en) Use of gaboxadol in the treatment of narcolepsy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075616

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1075616

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080507